Cargando…

A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis

Immunotherapy, a treatment based on host immune system activation, has been shown to provide a substitute for marginally effective conventional chemotherapy in controlling visceral leishmaniasis (VL), the deadliest form of leishmaniasis. As the majority of endemic inhabitants exhibit either subclini...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratnapriya, Sneha, Keerti, Yadav, Narendra Kumar, Dube, Anuradha, Sahasrabuddhe, Amogh Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164546/
https://www.ncbi.nlm.nih.gov/pubmed/34095312
http://dx.doi.org/10.1155/2021/8845826
_version_ 1783701139971112960
author Ratnapriya, Sneha
Keerti,
Yadav, Narendra Kumar
Dube, Anuradha
Sahasrabuddhe, Amogh Anant
author_facet Ratnapriya, Sneha
Keerti,
Yadav, Narendra Kumar
Dube, Anuradha
Sahasrabuddhe, Amogh Anant
author_sort Ratnapriya, Sneha
collection PubMed
description Immunotherapy, a treatment based on host immune system activation, has been shown to provide a substitute for marginally effective conventional chemotherapy in controlling visceral leishmaniasis (VL), the deadliest form of leishmaniasis. As the majority of endemic inhabitants exhibit either subclinical or asymptomatic infection which often develops into the active disease state, therapeutic intervention seems to be an important avenue for combating infections by stimulating the natural defense system of infected individuals. With this perspective, the present study focuses on two immunodominant Leishmania (L.) donovani antigens (triosephosphate isomerase and enolase) previously proved to be potent prophylactic VL vaccine candidates, for generating a recombinant chimeric antigen. This is based on the premise that in a heterogeneous population, a multivalent antigen vaccine would be required for an effective response against leishmaniasis (a complex parasitic disease). The resulting molecule rLdT-E chimeric protein was evaluated for its immunogenicity and immunotherapeutic efficacy. A Th1 stimulating adjuvant BCG was employed with the protein which showed a remarkable 70% inhibition of splenic parasitic multiplication positively correlated with boosted Th1 dominant immune response against lethal L. donovani challenge in hamsters as evidenced by high IFN-γ and TNF-α and low IL-10. In addition, immunological analysis of antibody subclass presented IgG2-based humoral response besides considerable delayed-type hypersensitivity and lymphocyte proliferative responses in rLdT-E/BCG-treated animals. Our observations indicate the potential of the chimera towards its candidature for an effective vaccine against Leishmania donovani infection.
format Online
Article
Text
id pubmed-8164546
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-81645462021-06-04 A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis Ratnapriya, Sneha Keerti, Yadav, Narendra Kumar Dube, Anuradha Sahasrabuddhe, Amogh Anant Biomed Res Int Research Article Immunotherapy, a treatment based on host immune system activation, has been shown to provide a substitute for marginally effective conventional chemotherapy in controlling visceral leishmaniasis (VL), the deadliest form of leishmaniasis. As the majority of endemic inhabitants exhibit either subclinical or asymptomatic infection which often develops into the active disease state, therapeutic intervention seems to be an important avenue for combating infections by stimulating the natural defense system of infected individuals. With this perspective, the present study focuses on two immunodominant Leishmania (L.) donovani antigens (triosephosphate isomerase and enolase) previously proved to be potent prophylactic VL vaccine candidates, for generating a recombinant chimeric antigen. This is based on the premise that in a heterogeneous population, a multivalent antigen vaccine would be required for an effective response against leishmaniasis (a complex parasitic disease). The resulting molecule rLdT-E chimeric protein was evaluated for its immunogenicity and immunotherapeutic efficacy. A Th1 stimulating adjuvant BCG was employed with the protein which showed a remarkable 70% inhibition of splenic parasitic multiplication positively correlated with boosted Th1 dominant immune response against lethal L. donovani challenge in hamsters as evidenced by high IFN-γ and TNF-α and low IL-10. In addition, immunological analysis of antibody subclass presented IgG2-based humoral response besides considerable delayed-type hypersensitivity and lymphocyte proliferative responses in rLdT-E/BCG-treated animals. Our observations indicate the potential of the chimera towards its candidature for an effective vaccine against Leishmania donovani infection. Hindawi 2021-02-27 /pmc/articles/PMC8164546/ /pubmed/34095312 http://dx.doi.org/10.1155/2021/8845826 Text en Copyright © 2021 Sneha Ratnapriya et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ratnapriya, Sneha
Keerti,
Yadav, Narendra Kumar
Dube, Anuradha
Sahasrabuddhe, Amogh Anant
A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
title A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
title_full A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
title_fullStr A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
title_full_unstemmed A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
title_short A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
title_sort chimera of th1 stimulatory proteins of leishmania donovani offers moderate immunotherapeutic efficacy with a th1-inclined immune response against visceral leishmaniasis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164546/
https://www.ncbi.nlm.nih.gov/pubmed/34095312
http://dx.doi.org/10.1155/2021/8845826
work_keys_str_mv AT ratnapriyasneha achimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT keerti achimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT yadavnarendrakumar achimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT dubeanuradha achimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT sahasrabuddheamoghanant achimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT ratnapriyasneha chimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT keerti chimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT yadavnarendrakumar chimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT dubeanuradha chimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis
AT sahasrabuddheamoghanant chimeraofth1stimulatoryproteinsofleishmaniadonovanioffersmoderateimmunotherapeuticefficacywithath1inclinedimmuneresponseagainstvisceralleishmaniasis